Shopping Cart 0
Cart Subtotal
USD 0

KOL Perspectives: Mid-to-Late Stage Pipeline Therapies in Lupus

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
USD 2500

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
USD 5000

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
USD 7500

Details

KOL Perspectives: Mid-to-Late Stage Pipeline Therapies in Lupus

Summary

This KOL Insight briefing focuses on opinions of mid- to late-stage pipeline therapies in lupus.

The briefing includes analysis of KOL opinion on the following topic areas-

- Development of Lupuzor for SLE

- Lupuzor's Phase III trial design

- Lupuzor's Phase IIb efficacy data in SLE

- Anticipated future use of Lupuzor in SLE

- Development of baricitinib in SLE

- Endpoints used in baricitinib's Phase II trial

- Expectations for baricitinib's Phase II trial results

- Views on the increased risk of thromboembolic events seen with baricitinib in RA

- Views on the risk of thromboembolic events in the lupus patient population

- Concerns regarding herpes zoster in lupus patients

- Impact of high infection rate with JAK inhibitor use in RA, on anticipated baricitinib use in SLE

- Development of IFN? kinoid in SLE

- IFN? kinoid vs. anifrolumab in SLE

Key Highlights

- Most KOLs flagged the need for more data to understand Lupuzor's mechanism of action and elucidate its efficacy in lupus patients

- KOLs were divided over Lupuzor's efficacy in lupus based on its Phase IIb data, with some highlighting that it may be comparable to belimumab

- Most KOLs had a positive opinion regarding baricitinib's development in lupus, based on its data in other indications.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders (KOLs)

- In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based

- Interviews performed in December 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Mid-to-Late Stage Pipeline Therapies in Lupus"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Table Of Content

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Lupus, baricitinib, Lupuzor


Companies

ImmuPharma

AstraZeneca

Lilly

Company Profile

Company Profile Title

KOL Perspectives: Mid-to-Late Stage Pipeline Therapies in Lupus

Summary

This KOL Insight briefing focuses on opinions of mid- to late-stage pipeline therapies in lupus.

The briefing includes analysis of KOL opinion on the following topic areas-

- Development of Lupuzor for SLE

- Lupuzor's Phase III trial design

- Lupuzor's Phase IIb efficacy data in SLE

- Anticipated future use of Lupuzor in SLE

- Development of baricitinib in SLE

- Endpoints used in baricitinib's Phase II trial

- Expectations for baricitinib's Phase II trial results

- Views on the increased risk of thromboembolic events seen with baricitinib in RA

- Views on the risk of thromboembolic events in the lupus patient population

- Concerns regarding herpes zoster in lupus patients

- Impact of high infection rate with JAK inhibitor use in RA, on anticipated baricitinib use in SLE

- Development of IFN? kinoid in SLE

- IFN? kinoid vs. anifrolumab in SLE

Key Highlights

- Most KOLs flagged the need for more data to understand Lupuzor's mechanism of action and elucidate its efficacy in lupus patients

- KOLs were divided over Lupuzor's efficacy in lupus based on its Phase IIb data, with some highlighting that it may be comparable to belimumab

- Most KOLs had a positive opinion regarding baricitinib's development in lupus, based on its data in other indications.

Scope

- The insight briefing is based on Sociable Pharma's analysis of primary research with our lupus key opinion leaders (KOLs)

- In total, we conducted interviews with 14 KOLs: Seven Europe-based & seven US-based

- Interviews performed in December 2017

- KOL data is analyzed to produce: Charts summarizing KOL opinions

- Chart call-outs of key information & details

- KOL quotes

- Summary of KOL reporting trends

- Insight from Sociable Pharma's analysts.

Reasons to buy

- Combines Qualitative & semi-quantitative insight from key opinion leaders on "Mid-to-Late Stage Pipeline Therapies in Lupus"

- Includes insight & recommendations from our disease-specific healthcare analysts

- Utilizes independent expert viewpoints to validate the impact of new clinical data & emerging trends on management of Lupus

- Provides cost-effective support for your advisory boards, with topics acting as a catalyst for further expert discussion.

READ MORE

Scope

Table of Contents

Executive Summary

Background

Research Panel Composition

Results & Implications

Appendix

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Lupus, baricitinib, Lupuzor


Companies

ImmuPharma

AstraZeneca

Lilly